Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21277813 | 1.00 | NCF1 (0.43) | NCF1TSHRALDH1A1TP53ATM | |
| SCHEMBL1700144 | 1.00 | NCF1 (0.43) | NCF1TSHRALDH1A1TP53ATM | |
| SCHEMBL954911 | 0.89 | TSHR (0.44) | NCF1TSHRALDH1A1ATMNPSR1 | |
| SCHEMBL964176 | 0.88 | NCF1 (0.52) | NCF1TSHRALDH1A1TP53ATM | |
| Hydrochloric Acid SCHEMBL927894 | 0.86 | NCF1 (0.50) | NCF1TSHRALDH1A1TP53ATM | |
| SCHEMBL16977563 | 0.84 | NCF1 (0.43) | NCF1TSHRALDH1A1TP53L3MBTL1 | |
| SCHEMBL23145045 | 0.83 | NCF1 (0.41) | NCF1ALDH1A1 | |
| SCHEMBL16977617 | 0.83 | NCF1 (0.34) | NCF1ALDH1A1TP53ATML3MBTL1 | |
| SCHEMBL10289418 | 0.82 | TP53 (0.43) | TSHRALDH1A1TP53ATML3MBTL1 | |
| SCHEMBL24456475 | 0.82 | TP53 (0.43) | TSHRALDH1A1TP53ATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236122-B2 | Triterpene amine derivatives | DFH THERAPEUTICS (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210253627-A1 | TRITERPENE AMINE DERIVATIVES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253627-A1 | TRITERPENE AMINE DERIVATIVES | BET1, PGGT1B, NFATC1 | NCF1 2119/4885TSHR 4117/4885ALDH1A1 3332/4885 |
| US-11236122-B2 | Triterpene amine derivatives | BET1, PGGT1B, NFATC1 | NCF1 2119/4885TSHR 4117/4885ALDH1A1 3332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.